REVIEW ARTICLE

Clinical, Tomographic and Histopathological Features of Lung Cancer Patients

Julio Ernesto Rodriguez Serret*, Odalis García Gómez, Sahily Salcedo Quintero, Ileana Rosell Nicieza, Laura Pons Porrata

“Dr. Juan Bruno Zayas Alfonso” Teaching General Hospital, Santiago de Cuba, Cuba

Abstract: In 2015, 61 patients diagnosed with lung cancer treated at the Radiology Service of “Dr. Juan Bruno Zayas Alfonso” Teaching General Hospital in Santiago de Cuba, were observed and conducted descriptive and cross-sectional studies to characterize them according to the variables of interest. The results were organized into frequency distributions and single-input and two-input tables were compiled to establish certain relationships between the variables. Male (55.7%), 60–69 age group (39.3%), history of chronic bronchitis in male and female (75.4%), cough as the main symptom (63.9%), peripheral localization (78.7%) and adenocarcinoma as the histological type (57.4%). At the time of diagnosis, most patients are at the last stage of the disease, so studies are recommended for all patients at risk.

Keywords: Lung cancer, Computed axial tomography, Lung neoplasia, Radiology service

1. Introduction

Lung cancer, one of the most common cancers in the world, is a disease caused by the malignant growth of respiratory cells, especially lung tissue[1].

Lung cancer was not considered an important disease until 1791, but in 1819 the features became published, when it was difficult to distinguish from tuberculosis[2].

In 1878, the malignant findings of lung cancer accounted for only 1% of the cancers observed in autopsy. In 1912, there were 374 cases in the medical literature[3].

Currently, it accounts for 15% of total cancer diagnoses and is the leading cause of cancer death worldwide. Overall 5-year survival generally does not exceed 15% despite new treatments are adopted.

In 2012, it occurred in approximately 1.8 million patients and caused an estimated 1.6 million deaths. It is worth noting that most cases are detected in stages III and IV of the disease[4].

In the United States, it occurs in about 225,000 patients, causing approximately 160,000 deaths per year, more than colon, breast, and prostate cancer combined[5].

Cuba is not exempt from this disease, as shown by the fact that it is the leading cause of death in the country. In addition, by the end of 2016, 5,535 people had died of this disease.

In particular in Santiago, Cuba, it is the second leading cause of death just after cardiovascular disease, with 443 deaths died from lung cancer in 2015, accounting for 42.07% of total cancer deaths aged 30 to 69 years[6].
At the end of the same year, the Juan Bruno Zayas Alfonso General Hospital had diagnosed 203 lung cancer patients and 36 deaths (annual report of chronic noncommunicable diseases), Provincial Health and Epidemic Prevention Statistics Center, Santiago de Cuba, Cuba, 2015.

Lung cancer is a heterogeneous disease at the clinical, biological, histological and molecular levels. Traditionally, it is divided into two categories according to different disease types and treatment strategies: non-small cell or non-small cell lung cancer and small cell or small cell lung cancer[7].

On the other hand, there are four basic types of invasive lung tumors: squamous cell carcinoma or epidermoid carcinoma, adenocarcinoma, large cell carcinoma and small cell carcinoma[8].

The symptoms will depend on the location of the tumor, that is, if the patient has ineffective cough, mucopurulent sputum, hemoptysis, dyspnea and wheezing, which are central symptoms. If it is peripheral, inhalation chest pain and dysphonia. Other symptoms will depend on the presence of metastasis and paraneoplastic tumors[9].

Today, the detection methods of lung cancer are based on new imaging techniques, tumor markers and biopsy procedures[10].

Despite the use of new imaging research techniques, the disease is still in the late stage of diagnosis due to the high morbidity and mortality in Cuba. At present, it is a major health problem, which is the motivation of this study.

2. Methods

In 2015, 61 patients with lung cancer diagnosed by histopathology and CT axial scanning treated at the Radiology Service of “Dr. Juan Bruno Zayas Alfonso” Teaching General Hospital in Santiago de Cuba, were observed and conducted descriptive and cross-sectional studies.

The variables analyzed included age, history of chronic respiratory diseases, signs and symptoms, as well as the location and size of tumors.

Using the SPSS 11.5 operating system, the results were organized by frequency distribution. The percentage was also used as a summary indicator and one- and two-entry tables were prepared to establish some relationships between variables.

3. Results

Among the patients diagnosed with lung cancer during the study period, 55.7% were male and 39.3% were 60–69 years old.

As shown in Table 1, patients with a history of chronic bronchitis (75.4%) were common in both men and women, followed by emphysema (63.9%).

| History of chronic respiratory disease | Gender | No. | % | Male | No. | % | Total |
|--------------------------------------|--------|-----|---|------|-----|---|-------|
| Bronchial asthma                     | Female | 6   | 9.8 | 4    | 6.6 |   | 10    |
| Chronic bronchitis                   | Female | 22  | 36.1| 24   | 39.3|   | 46    |
| Bronchiectasis                       | Female | 18  | 29.5| 12   | 19.6|   | 30    |
| Emphysema                            | Female | 18  | 29.5| 21   | 34.4|   | 39    |
| No criminal record                   | Female | 9   | 14.8| 6    | 9.8 |   | 15    |

In the case group (Table 2), the main symptoms included cough (63.9%), general symptoms (57.4%) and dyspnea (50.8%). After the location analysis of these data, it was found that the symptoms of the patients with central lung cancer were mainly cough (92.3%), expectoration (84.6%) and hemoptysis (76.9%), but in the patients with peripheral lung cancer, cough (56.2%), general symptoms (54.1%) and dyspnea (47.9%).

The main sites (Table 3) were peripheral (78.7%) and infiltrative (75.4%). In addition, the most common histological type in the two sites (Table 4) was adenocarcinoma (57.4%), mainly in the central site (84.6%).

By analyzing the tumor size of patients with adenocarcinoma (Table 5), 3–5 cm (22.9%) was dominant and 5–7 cm (21.3%) was next. In addition, three of four tumors with less than 3 cm correspond to tumors of this type.

4. Discussion

The possibility of lung cancer for patients with respiratory diseases has been proposed. Some factors, such as chronic bronchitis, tuberculosis, bronchiectasis, pulmonary infarction area, foreign body inclusion, idiopathic pulmonary fibrosis, scleroderma and scars of other nature, may be the cause of lung cancer[11].

This series of results on age are consistent with that of Badui[12], who found that the number of lung cancer patients aged 60–69 was dominant.

In a study in Chile, Saldias et al.[13] confirmed that 66% of cancer patients had COPD by spirometry. Paradoxically, Yanes et al.[14] concluded that 66.4% of the case group members had no history of respiratory diseases.
Table 2. Patient statistics based on symptoms, signs and tumor location

| Symptoms and signs | Tumor localization | Total |
|-------------------|--------------------|-------|
|                   | Central n = 13     |       |
|                   | Peripheral n = 48  |       |
|                   | Total n = 61       |       |
| No. %*            | No. %*             | No. %**|
| Cough             | 12 92.3            | 27 56.2 | 39 63.9 |
| Expectorant       | 11 84.6            | 13 27.1 | 24 39.3 |
| Chest pain        | 4 30.7             | 17 35.4 | 21 34.4 |
| Dyspnea           | 8 61.5             | 23 47.9 | 31 50.8 |
| Hemoptysis        | 10 76.9            | 3 6.2   | 13 21.3 |
| General symptoms  | 9 69.2             | 26 54.1 | 35 57.4 |

*Percentage of the total number by location  
**Percentage calculated from the total number of patients

Table 3. Patient statistics based on the location of the tumor

| Tumor localization | No. | %  |
|--------------------|-----|----|
| Central Bronchitis | 11  | 18.0 |
| Bronchial obstruction | 2  | 3.3 |
| Subtotal           | 13  | 21.3 |
| Peripheral Nodular | 2   | 3.3 |
| Penetrating        | 46  | 75.4 |
| Subtotal           | 48  | 78.7 |
| Total              | 61  | 100.0 |

Table 4. Patient statistics based on the histological type and tumor location

| Organization type         | Tumor localization | Total |
|---------------------------|--------------------|-------|
|                           | Central No. %*     | Peripheral No. %* | No. %** |
| Epidermoid                | 1 7.6              | 5 10.4 | 6 9.8 |
| Adenocarcinoma            | 11 84.6            | 24 50.0 | 35 57.4 |
| Small cell carcinoma      | 1 7.6              | 4 8.3  | 5 8.2 |
| Large cell carcinoma      | 0 0.0              | 11 22.9 | 11 18.0 |
| Glandular squamous        | 0 0.0              | 4 8.3  | 4 6.6 |
| Total**                   | 13 21.3            | 48 78.7 | 61 100.0 |

*Percentages calculated on the basis of the total by columns  
**Percentage calculated based on the total number of patients

Table 5. Patient statistics based on tumor histological type and tumor size

| Organization type         | Tumor size (cm) | Total |
|---------------------------|-----------------|-------|
|                           | Less than 2     | 2–3   | 3–5   | 5–7   | More than 7 | No. % |
| Epidermoid                | No. %           | No. % | No. % | No. % | No. %       |      |
| Adenocarcinoma            | 2 3.3           | 1 1.6 | 14 22.9 | 13 21.3 | 5 8.2 | 35 57.4 |
| Small cell                | 0.0             | 2 3.3 | 3 4.9  | 5 8.2  |
| Large cell                | 1 1.6           | 4 6.6 | 4 6.6  | 2 3.3  | 11 18.0 |
| Glandular squamous        | 2 3.3           | 2 3.3 | 2 3.3  | 4 6.6  |
| Total                     | 2 3.3           | 2 3.3 | 22 36.0 | 25 41.0 | 10 16.4 | 61 100.0 |

With regard to symptoms, most authors agree that intrabronchial growth leads to cough, hemoptysis, wheezing and dyspnea. At the same time, there are surrounding tumors, chest pain, cough, dyspnea and abscess\(^{[15]}\).

Other researchers in the subject\(^{[16,17]}\) pointed out that malignant lesions spread around in the form of nodules and masses. The results are similar to the location described in this study.

According to histology, the division of scientific standards is determined. Therefore, it is necessary to consult the classic literature of this specialty, and it is agreed that most adenocarcinoma shows peripheral lesions with increased central location\(^{[17,18]}\).

A recent study showed that the larger the nodule, the greater the risk of malignancy\(^{[19]}\). In this regard, in a
similar study\cite{12}, most tumors are more than 3cm, which reaffirms the delayed diagnosis of this kind of cancer.

At the time of diagnosis, most patients are in the advanced stage of the disease, so it is recommended to study all patients at risk.

Conflict of interest

Authors declared no conflict of interest.

References

1. MedlinePlus, Lung Cancer. Available from: http://www.nlm.nih.gov/medlineplus/spanish/lungcancer.html.
2. Olson JS, 1989, The History of Cancer: An Annotated Bibliography. New York: Greenwood Press. Available from: https://books.google.com.cu/books?id=oAX8jOJ9oOOC&pg=PR3&source=gbs_selected_pages&cad=2#v=onepage&q&f=false.
3. Hanspeter W, 2001, A Short History of Lung Cancer. *Toxicol Sci*, 64:4–6. DOI: 10.1093/toxsci/64.1.4.
4. Toh CK, 2009, The Changing Epidemiology of Lung Cancer. *Methods Mol Biol*, 472:397–411. DOI: 10.1007/978-1-60327-492-019.
5. Siegel RL, Miller KD, Jemal A, 2017, Cancer Statistics. *CA Cancer J Clin*, 67:7–30.
6. Bureau of Medical Records and Health Statistics, Ministry of Health, Cuba, 2016, Cuban Health Statistics Yearbook. Havana: MINSAP. Available from: http://files.sld.cu/dne/files/2017/05/Anuario_Estadístico_de_Salud_e_2016_edición_2017.pdf.
7. San Ildefonso F, Aloyo Díaz A, *Análisis De Polimorfismos En Genes Que Codifican Para Enzimas Que Regulan El Estrés Oxidativo Y Su Relación Con La Respuesta Al Tratamiento Y La Supervivencia En Pacientes Con Cáncer De Pulmón*. [Analysis of Oxidative Stress Regulatory Enzyme Gene Polymorphism in Patients with Lung Cancer and Its Relationship with Treatment Response and Survival]. PhD thesis, School of Medicine and Dentistry, University of Valencia. Available from: http://roderic.uv.es/bitstream/handle/10550/50607/TESIS%20FINAL.pdf?sequence=1&isAllowed=y.
8. American Society Cancer. Risk Factors for Lung Cancer. Available from: https://www.cancer.org/es/cancer/cancer-de-pulmon/preencion-y-detencion-temprana/factores-de-riesgo.html.
9. Ruano Ravina A, Pérez Rios M, Fernández-Villar A, 2013, Lung Cancer Screening with Low-Dose Computed Tomography after the National Lung Screening Trial. The Debate is Still Open. Arch Bronconeumol, 49.
10. Barroso Mercado CE, 2014, Estado Actual Del Tratamiento En Cáncer De Pulmón: Revisión Sistemática De La Literatura [Barroso Market Current Status of Lung Cancer Treatment: A Systematic Literature Review]. thesis, The National Autonomous University of Mexico. Available from: http://ri.uaemex.mx/bitstream/handle/20.500.11799/14882/Tesis.417831.pdf?sequence=2.
11. Farreras P, Rozman C, 2016, Medicina interna. Neumología. Tumores broncopulmonares. [Internal Medicine Pulmonary Disease Bronchopulmonary Tumor] (18th edn.). Barcelona: Elsevier.
12. Badou N, 2012, Nódulo Pulmonar Solitario, Abordaje Diagnóstico [Solitary Pulmonary Nodule, Diagnostic Method]. MEDFAMPUI. Available from: https://preventiva.wordpress.com/2012/09/25/nodulo-pulmonar-solitario-abordaje-diagnostico/.
13. Saldivia Peñafiel F, Elola Aránguiz JM, Uribe Monasterio J, et al., 2016, Risk Factors for the Development of Lung Cancer in a Cohort of Adult Smokers. *Rev Méd Chile*, 144. DOI: 10.4067/S0034-98872016001100003.
14. Yanes Quesada MA, Ayala Escobar M, Yanes Quesada M, *et al.*, 2015, Enfoque Práctico En La Asociación De La Clínica Con La Variedad Histológica En El Cáncer Del Pulmón [Practical Approach in the Association of the Clinical with Histologic Variety in Lung Cancer]. *Rev Cubana Med*, 54.
15. Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM), 2013, A Genomics-based Classification of Human Lung Tumors. *Sci Transl Med*, 5. DOI: 10.1126/scitranslmed.3006802.
16. Di Muzio B, Danaher L, 2017, Small-cell Lung Cancer. Available from: https://radiopaedia.org/articles/small-cell-lung-cancer-2.
17. Sánchez Pedrosa C, Casanova R, 2004, Generalidades. Aparato respiratorio y cardiovascular [General Information. Respiratory and Cardiovascular System]. In: Tratado de diagnóstico por imagen [Treatise on Diagnostic Imaging] (2nd edn.). Madrid: McGraw-Hill Interamericana, pp.567–92.
18. Blajot Pena M, 2006, Radiología Clínica del Tórax [Clinical Chest Radiology] (2nd edn.). Barcelona: Ediciones Toray, pp.275–324.
19. Weinberger S, McDermott S, 2016, Diagnostic, Evaluation and Management of the Solitary Pulmonary Nodule. Available from: https://www.uptodate.com/contents/diagnostic-evaluation-of-the-incidentalpulmonary-nodule.